Patents by Inventor William C. Fanslow, III
William C. Fanslow, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090324597Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: ApplicationFiled: August 4, 2008Publication date: December 31, 2009Applicant: IMMUNEX CORPORATIONInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Publication number: 20090263383Abstract: The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD148. Compositions of the invention include: anti-CD148 antibodies, antigen binding regions of anti-CD148 antibodies, polynucleotides encoding anti-CD 148 antibodies or binding regions thereof, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions is also provided.Type: ApplicationFiled: February 27, 2008Publication date: October 22, 2009Applicant: Amgen Inc.Inventors: James F. Smothers, William C. Fanslow, III, Revital Kariv
-
Publication number: 20090137036Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: ApplicationFiled: January 16, 2009Publication date: May 28, 2009Inventors: KRISTINE M. KIM, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Patent number: 7495086Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: October 22, 2004Date of Patent: February 24, 2009Assignee: Immunex CorporationInventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Patent number: 7449555Abstract: Anti-CD148 antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind CD148 epitopes and activate CD148 function, such as inhibition of angiogenesis. Epitopes that can be used to activate CD148 function and anti-angiogenesis activity are also described, as well as methods of identifying compounds that can bind them.Type: GrantFiled: April 22, 2005Date of Patent: November 11, 2008Assignee: Amgen Inc.Inventors: William C. Fanslow, III, Revital Kariv, James F. Smothers
-
Patent number: 7427669Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: December 13, 2006Date of Patent: September 23, 2008Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 7405270Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.Type: GrantFiled: July 19, 2002Date of Patent: July 29, 2008Assignee: Immunex CorporationInventors: Richard J. Armitage, William C. Fanslow, III, Melanie K. Spriggs
-
Patent number: 7193058Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: June 23, 2004Date of Patent: March 20, 2007Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 7175849Abstract: This invention relates to nectin polypeptides and polynucleotides, to methods of making such polypeptides and polynucleotides, and to methods of using such polypeptides and polynucleotides to modulate cell adhesion, cell migration, and angiogenesis, to treat conditions related to cell adhesion including endothelial and epithelial cell proliferation, migration, and barrier function, and to identify agents that alter nectin polypeptide activities.Type: GrantFiled: October 5, 2001Date of Patent: February 13, 2007Assignee: Immunex CorporationInventors: Peter R Baum, William C Fanslow, III, Timothy E Lofton, Eric A Sorensen, Adel Youakim
-
Patent number: 7074408Abstract: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.Type: GrantFiled: February 23, 2001Date of Patent: July 11, 2006Assignee: Immunex CorporationInventors: William C. Fanslow, III, Douglas P. Cerretti, Kurt M. Poindexter, Roy A. Black
-
Patent number: 7067475Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.Type: GrantFiled: February 3, 2003Date of Patent: June 27, 2006Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Luis G. Borges, William C. Fanslow, III
-
Patent number: 6774224Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 5, 2002Date of Patent: August 10, 2004Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 6762030Abstract: The invention relates to CD7 and the discovery of its cognate ligand, the K12 protein, and the identification and cloning of polynucletides that encode the murine homolog of the human K12. Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the interaction between CD7 and K12. The use of the antagonists and agonists, including soluble K12 proteins, as therapeutics to treat diseases modulated by CD7 are also disclosed.Type: GrantFiled: November 27, 2001Date of Patent: July 13, 2004Assignee: Immunex CorporationInventors: Stewart D. Lyman, William C. Fanslow, III
-
Patent number: 6653447Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: March 13, 2000Date of Patent: November 25, 2003Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 6613320Abstract: CD4+ cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described.Type: GrantFiled: April 10, 2000Date of Patent: September 2, 2003Assignee: Immunex CorporationInventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer, Barry L. Davison, Blair R. Renshaw
-
Patent number: 6521424Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization. Also provided are materials and methods for recombinant expression of Tek antagonists.Type: GrantFiled: December 7, 2000Date of Patent: February 18, 2003Assignee: Immunex CorporationInventors: Douglas P. Cerretti, William C. Fanslow, III
-
Patent number: 6458350Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: March 22, 2000Date of Patent: October 1, 2002Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 6106832Abstract: There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating individuals exhibiting a defective CD40 ligand gene (i.e., X-linked hyper IgM patients and certain individuals afflicted with combined variable immunodeficiency) are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.Type: GrantFiled: January 22, 1996Date of Patent: August 22, 2000Assignee: Immunex CorporationInventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer
-
Patent number: 5900238Abstract: Compositions comprising an immunogenic amount of an antigen encapsulated in a stabilized hydrogel microbead are disclosed. The compositions provide a delivery system for antigens such as vaccines. Also provided are methods of stimulating an immune response comprising administration of the inventive compositions.Type: GrantFiled: July 27, 1995Date of Patent: May 4, 1999Assignee: Immunex CorporationInventors: Wayne R. Gombotz, Siow Fong Wee, William C. Fanslow, III
-
Patent number: 5801227Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to CD40 and are capable of blocking binding of CD40 to CD40 ligand.Type: GrantFiled: September 8, 1995Date of Patent: September 1, 1998Inventors: William C. Fanslow, III, JoDee Zappone, Mark Alderson, Richard J. Armitage